BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 294 filers reported holding BIO-TECHNE CORP in Q4 2017. The put-call ratio across all filers is 1.23 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,926,449 | -31.0% | 28,301 | -17.3% | 0.00% | 0.0% |
| Q2 2023 | $2,793,460 | +33.4% | 34,221 | +21.2% | 0.00% | 0.0% |
| Q1 2023 | $2,094,829 | -7.4% | 28,236 | +3.5% | 0.00% | 0.0% |
| Q4 2022 | $2,261,878 | +20.9% | 27,291 | +314.0% | 0.00% | 0.0% |
| Q3 2022 | $1,871,000 | -30.4% | 6,592 | -14.9% | 0.00% | 0.0% |
| Q2 2022 | $2,687,000 | -58.4% | 7,748 | -48.0% | 0.00% | -50.0% |
| Q1 2022 | $6,458,000 | -56.0% | 14,911 | -47.5% | 0.00% | -50.0% |
| Q4 2021 | $14,683,000 | +11.2% | 28,383 | +4.2% | 0.00% | 0.0% |
| Q3 2021 | $13,200,000 | +32.3% | 27,241 | +22.9% | 0.00% | +33.3% |
| Q2 2021 | $9,977,000 | +14.2% | 22,158 | -3.1% | 0.00% | 0.0% |
| Q1 2021 | $8,735,000 | +23.9% | 22,870 | +3.0% | 0.00% | +50.0% |
| Q4 2020 | $7,051,000 | +41.3% | 22,203 | +10.2% | 0.00% | 0.0% |
| Q3 2020 | $4,991,000 | +474.3% | 20,149 | +511.9% | 0.00% | – |
| Q2 2020 | $869,000 | -11.5% | 3,293 | -36.4% | 0.00% | – |
| Q1 2020 | $982,000 | -89.2% | 5,177 | -87.5% | 0.00% | -100.0% |
| Q4 2019 | $9,073,000 | +147.2% | 41,335 | +120.3% | 0.00% | +200.0% |
| Q3 2019 | $3,671,000 | +286.4% | 18,763 | +312.2% | 0.00% | – |
| Q2 2019 | $950,000 | -15.6% | 4,552 | -19.8% | 0.00% | – |
| Q1 2019 | $1,126,000 | +55.1% | 5,674 | +13.2% | 0.00% | – |
| Q4 2018 | $726,000 | -64.9% | 5,013 | -50.5% | 0.00% | -100.0% |
| Q3 2018 | $2,068,000 | +65.7% | 10,132 | +20.2% | 0.00% | 0.0% |
| Q2 2018 | $1,248,000 | -56.2% | 8,430 | -55.3% | 0.00% | 0.0% |
| Q1 2018 | $2,850,000 | +96.8% | 18,870 | +68.8% | 0.00% | 0.0% |
| Q4 2017 | $1,448,000 | -26.1% | 11,180 | -31.0% | 0.00% | 0.0% |
| Q3 2017 | $1,960,000 | +203.9% | 16,211 | +194.9% | 0.00% | – |
| Q2 2017 | $645,000 | +3.0% | 5,497 | -10.7% | 0.00% | – |
| Q1 2017 | $626,000 | -21.2% | 6,158 | -20.2% | 0.00% | – |
| Q4 2016 | $794,000 | -49.4% | 7,717 | -46.2% | 0.00% | -100.0% |
| Q3 2016 | $1,570,000 | +3.7% | 14,336 | +6.8% | 0.00% | 0.0% |
| Q2 2016 | $1,514,000 | +60.4% | 13,418 | +34.2% | 0.00% | 0.0% |
| Q1 2016 | $944,000 | +113.6% | 9,995 | +103.8% | 0.00% | – |
| Q4 2015 | $442,000 | +79.7% | 4,904 | +84.3% | 0.00% | – |
| Q3 2015 | $246,000 | -66.6% | 2,661 | -64.4% | 0.00% | – |
| Q2 2015 | $736,000 | -51.0% | 7,481 | -50.1% | 0.00% | -100.0% |
| Q1 2015 | $1,502,000 | -40.2% | 14,979 | -44.9% | 0.00% | -50.0% |
| Q4 2014 | $2,511,000 | – | 27,175 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |